- Home
- GDST vs INAB Comparison
GDST vs INAB Comparison
Compare GDST & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDST
- INAB
- Stock Information
- Founded
- GDST 2020
- INAB 2016
- Country
- GDST United States
- INAB United States
- Employees
- GDST N/A
- INAB N/A
- Industry
- GDST
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- GDST
- INAB Health Care
- Exchange
- GDST NYSE
- INAB Nasdaq
- Market Cap
- GDST N/A
- INAB 24.0M
- IPO Year
- GDST 2022
- INAB 2021
- Fundamental
- Price
- GDST $11.29
- INAB $0.25
- Analyst Decision
- GDST
- INAB Strong Buy
- Analyst Count
- GDST 0
- INAB 3
- Target Price
- GDST N/A
- INAB $7.75
- AVG Volume (30 Days)
- GDST 125.0
- INAB 727.4K
- Earning Date
- GDST 01-01-0001
- INAB 11-12-2024
- Dividend Yield
- GDST N/A
- INAB N/A
- EPS Growth
- GDST 111.15
- INAB N/A
- EPS
- GDST 0.23
- INAB N/A
- Revenue
- GDST N/A
- INAB N/A
- Revenue This Year
- GDST N/A
- INAB N/A
- Revenue Next Year
- GDST N/A
- INAB N/A
- P/E Ratio
- GDST $49.87
- INAB N/A
- Revenue Growth
- GDST N/A
- INAB N/A
- 52 Week Low
- GDST $10.73
- INAB $0.22
- 52 Week High
- GDST $12.45
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- GDST 80.29
- INAB 39.26
- Support Level
- GDST N/A
- INAB $0.28
- Resistance Level
- GDST $11.31
- INAB $0.32
- Average True Range (ATR)
- GDST 0.00
- INAB 0.03
- MACD
- GDST 0.01
- INAB -0.01
- Stochastic Oscillator
- GDST 81.82
- INAB 13.73
About GDST GOLDENSTONE ACQUISITION LIMITED
Goldenstone Acquisition Ltd is a newly organized blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.